The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 05, 2016
Filed:
Jul. 20, 2011
Scott B. Hoyt, Hoboken, NJ (US);
Min K. Park, Whippany, NJ (US);
Clare London, Chatham, NJ (US);
Yusheng Xiong, Plainsboro, NJ (US);
D. Jonathan Bennett, Aberdour, GB;
Jiaqiang Cai, Glasgow, GB;
Paul Ratcliffe, Strathaven, GB;
Andrew Cooke, East Kilbride, GB;
Emma Carswell, Eaglesham, GB;
John Maclean, Kilmarnock, GB;
Rohit Saxena, Uttar Pradesh, IN;
Bheemashankar A. Kulkarni, Karnataka State, IN;
Archana Gupta, Uttar Pradesh, IN;
Scott B. Hoyt, Hoboken, NJ (US);
Min K. Park, Whippany, NJ (US);
Clare London, Chatham, NJ (US);
Yusheng Xiong, Plainsboro, NJ (US);
D. Jonathan Bennett, Aberdour, GB;
Jiaqiang Cai, Glasgow, GB;
Paul Ratcliffe, Strathaven, GB;
Andrew Cooke, East Kilbride, GB;
Emma Carswell, Eaglesham, GB;
John MacLean, Kilmarnock, GB;
Rohit Saxena, Uttar Pradesh, IN;
Bheemashankar A. Kulkarni, Karnataka State, IN;
Archana Gupta, Uttar Pradesh, IN;
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.